Vulsteke, C.; De Cocker, L.; Gómez de Liaño, A.; Montesdeoca, C.; De Meulenaere, A.; Croes, L.; Delombaerde, D.; Szabados, B.; Powles, T.
First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients. Pharmaceuticals 2023, 16, 375.
https://doi.org/10.3390/ph16030375
AMA Style
Vulsteke C, De Cocker L, Gómez de Liaño A, Montesdeoca C, De Meulenaere A, Croes L, Delombaerde D, Szabados B, Powles T.
First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients. Pharmaceuticals. 2023; 16(3):375.
https://doi.org/10.3390/ph16030375
Chicago/Turabian Style
Vulsteke, Christof, Laurens De Cocker, Alfonso Gómez de Liaño, Cristina Montesdeoca, Astrid De Meulenaere, Lieselot Croes, Danielle Delombaerde, Bernadett Szabados, and Thomas Powles.
2023. "First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients" Pharmaceuticals 16, no. 3: 375.
https://doi.org/10.3390/ph16030375
APA Style
Vulsteke, C., De Cocker, L., Gómez de Liaño, A., Montesdeoca, C., De Meulenaere, A., Croes, L., Delombaerde, D., Szabados, B., & Powles, T.
(2023). First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients. Pharmaceuticals, 16(3), 375.
https://doi.org/10.3390/ph16030375
